Abstract
During the COVID-19 pandemic it was widely described that certain individuals infected by SARS-CoV-2 experience persistent disease signs and symptoms, Long COVID, which in some cases is very severe with life changing consequences. To maximize our chances of identifying the underpinnings of this illness, we have focused on 121 of the most severe cases from >1000 patients screened in specialized clinics in Sweden and Belgium. We restricted this study to subjects with objective measures of organ damage or dysfunction, >3 months following a verified, but mild-to-moderate SARS-CoV-2 infection. By performing systems-level immunological testing and comparisons to controls fully convalescent following a similar mild/moderate COVID-19 episode, we identify elevated serological responses to SARS-CoV-2 in severe Long COVID suggestive of chronic antigen stimulation. Persistent viral reservoirs have been proposed in Long COVID and using multiple orthogonal methods for detection of SARS-CoV-2 RNA and protein in plasma we identify a subset of patients with detectable antigens, but with minimal overlap across assays, and no correlation to symptoms or immune measurements. Elevated serologic responses to SARS-CoV-2 on the other hand were inversely correlated with clonally expanded memory CD8+ T cells, indicating that restrained clonal expansion enables viral persistence, chronic antigen exposure and elevated IgG responses, even if antigen-detection in blood is not universally possible.
Competing Interest Statement
P.B, J.M and T.L are founders and shareholders of Cytodelics AB developing blood stabilizer solutions used in this study. P.B is an executive board member of Kancera AB (Stockholm, Sweden). D.W has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the SIMOA technology, a founder of the company, and also serves on its Board of Directors. Dr. Walt's interests were reviewed and are managed by Brigham and Women's Hospital and Partners Healthcare in accordance with their conflict-of- interest policies.
Funding Statement
This work is supported by the HORIZON HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE) and the Swedish research council (2021-06529) and Knut & Alice Wallenberg Foundation (VC-2021- 0026). The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute and the Rockefeller University and St. Giles Foundation and the Fisher Center for Alzheimers Research Foundation and the Meyer Foundation and the JPB Foundation. Also the French National Research Agency (ANR) under the Investments for the Future program (ANR-10-IAHU-01) and the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID) and the French Foundation for Medical Research (FRM) (EQU201903007798) and the ANRS-COV05 and ANR GENVIR (ANR-20-CE93-003). Also the European Unions Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-genomics) and the ANR-RHU COVIFERON Program (ANR-21-RHUS-08) and the Square Foundation and Grandir - Fonds de solidarite pour lenfance and the Fondation du Souffle and the SCOR Corporate Foundation for Science and Battersea & Bowery Advisory Group and William E. Ford General Atlantics Chairman and Chief Executive Officer and Gabriel Caillaux and the General Atlantics Co-President and Managing Director and Head of business in EMEA and the General Atlantic Foundation and the French Ministry of Higher Education and Research and Innovation (MESRI-COVID-19). Institut National de la Sante et de la Recherche Medicale (INSERM) and REACTing-INSERM and the University of Paris Cite.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Swedish Ethical Review Authority (Dnr 2021-03293).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the code to reproduce figures is in our dedicated GitHub study repository: https://github.com/Brodinlab/LongCOVID_Sweden_Belgium. This also includes processed data required for analyses while raw cytometry data is uploaded to FlowRepository.org: https://flowrepository.org/id/FR-FCM-Z76S.
